The BBI Dictionary of English Word Combinations

does not fit all. Proceedings of the National Academy of Sciences of the United States of America 112:E472-

477.

96. Rosenblum, E., S. McBane, W. Wang, and M. Sawyer. 2014. Protecting newborns by immunizing

family members in a hospital-based vaccine clinic: a successful Tdap cocooning program during the 2010 California pertussis epidemic. Public health reports 129:245-251.

97. Healy, C. M., M. A. Rench, S. H. Wootton, and L. A. Castagnini. 2014. Evaluation of the Impact of a

Pertussis Cocooning Program on Infant Pertussis Infection. The Pediatric infectious disease journal. 98. Urwyler, P., and U. Heininger. 2014. Protecting newborns from pertussis - the challenge of complete

cocooning. BMC infectious diseases 14:397.

99. Warfel, J. M., J. F. Papin, R. F. Wolf, L. I. Zimmerman, and T. J. Merkel. 2014. Maternal and neonatal

vaccination protects newborn baboons from pertussis infection. The Journal of infectious diseases

210:604-610.

100. Haberling, D. L., R. C. Holman, C. D. Paddock, and T. V. Murphy. 2009. Infant and maternal risk factors

for pertussis-related infant mortality in the United States, 1999 to 2004. The Pediatric infectious disease journal 28:194-198.

101. Wood, N., and C. A. Siegrist. 2011. Neonatal immunization: where do we stand? Current opinion in

infectious diseases 24:190-195.

102. Keller-Stanislawski, B., J. A. Englund, G. Kang, P. Mangtani, K. Neuzil, H. Nohynek, R. Pless, P. Lambach, and P. Zuber. 2014. Safety of immunization during pregnancy: a review of the evidence of

selected inactivated and live attenuated vaccines. Vaccine 32:7057-7064.

103. Munoz, F. M., N. H. Bond, M. Maccato, P. Pinell, H. A. Hammill, G. K. Swamy, E. B. Walter, L. A. Jackson, J. A. Englund, M. S. Edwards, C. M. Healy, C. R. Petrie, J. Ferreira, J. B. Goll, and C. J. Baker. 2014. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization

during pregnancy in mothers and infants: a randomized clinical trial. Jama 311:1760-1769.

104. Vilajeliu, A., A. Gonce, M. Lopez, J. Costa, L. Rocamora, J. Rios, I. Teixido, J. M. Bayas, and P. W. Group. 2015. Combined tetanus-diphtheria and pertussis vaccine during pregnancy: transfer of maternal

pertussis antibodies to the newborn. Vaccine 33:1056-1062.

105. Abu Raya, B., I. Srugo, A. Kessel, M. Peterman, D. Bader, R. Gonen, and E. Bamberger. 2014.

The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels - a prospective study. Vaccine 32:5787-5793.

106. Amirthalingam, G., N. Andrews, H. Campbell, S. Ribeiro, E. Kara, K. Donegan, N. K. Fry, E. Miller, and M. Ramsay. 2014. Effectiveness of maternal pertussis vaccination in England: an observational study.

Lancet 384:1521-1528.

107. Dabrera, G., G. Amirthalingam, N. Andrews, H. Campbell, S. Ribeiro, E. Kara, N. K. Fry, and M. Ramsay. 2015. A case-control study to estimate the effectiveness of maternal pertussis vaccination in

protecting newborn infants in England and wales, 2012-2013. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 60:333-337.

108. WHO 2014, posting date. WHO SAGE pertussis working group. Background paper April 2014 [Online.]

109. di Tommaso, A., M. T. de Magistris, M. Bugnoli, I. Marsili, R. Rappuoli, and S. Abrignani. 1994.

Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing. Infection and immunity 62:1830-1834.

110. Peppoloni, S., M. Pizza, M. T. De Magistris, A. Bartoloni, and R. Rappuoli. 1995. Acellular pertussis

vaccine composed of genetically inactivated pertussis toxin. Physiological chemistry and physics and medical NMR 27:355-361.

111. Robbins, J. B., R. Schneerson, B. Trollfors, H. Sato, Y. Sato, R. Rappuoli, and J. M. Keith. 2005. The

diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. The Journal of infectious diseases 191:81-88.

112. Fedele, G., M. Bianco, and C. M. Ausiello. 2013. The virulence factors of Bordetella pertussis: talented

modulators of host immune response. Archivum immunologiae et therapiae experimentalis 61:445-457.

113. Sebo, P., R. Osicka, and J. Masin. 2014. Adenylate cyclase toxin-hemolysin relevance for pertussis

vaccines. Expert review of vaccines 13:1215-1227.

114. Wang, X., and J. A. Maynard. 2015. The Bordetella Adenylate Cyclase Repeat-in-Toxin (RTX) Domain Is

Immunodominant and Elicits Neutralizing Antibodies. The Journal of biological chemistry 290:3576-3591.

115. de Gouw, D., M. I. de Jonge, P. W. Hermans, H. J. Wessels, A. Zomer, A. Berends, C. Pratt, G. A. Berbers, F. R. Mooi, and D. A. Diavatopoulos. 2014. Proteomics-identified Bvg-activated autotransporters

protect against bordetella pertussis in a mouse model. PloS one 9:e105011.

116. de Gouw, D., D. O. Serra, M. I. de Jonge, P. W. M. Hermans, H. J. C. T. Wessels, A. Zomer, O. M. Yantorno, D. A. Diavatopoulos, and F. R. Mooi. 2014. The vaccine potential of Bordetella pertussis

biofilm-derived membrane proteins. Emerg Microbes Infect 3:e58.

117. Dunne, A., P. J. Ross, E. Pospisilova, J. Masin, A. Meaney, C. E. Sutton, Y. Iwakura, J. Tschopp, P. Sebo, and K. H. Mills. 2010. Inflammasome activation by adenylate cyclase toxin directs Th17 responses

118. Fedele, G., F. Spensieri, R. Palazzo, M. Nasso, G. Y. Cheung, J. G. Coote, and C. M. Ausiello. 2010.

Bordetella pertussis commits human dendritic cells to promote a Th1/Th17 response through the activity of adenylate cyclase toxin and MAPK-pathways. PloS one 5:e8734.

119. Higgins, S. C., A. G. Jarnicki, E. C. Lavelle, and K. H. Mills. 2006. TLR4 mediates vaccine-induced

protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. Journal of immunology

177:7980-7989.

120. Ausiello, C. M., F. Urbani, A. la Sala, R. Lande, and A. Cassone. 1997. Vaccine- and antigen-dependent

type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infection and immunity 65:2168-2174.

121. Ryan, M., G. Murphy, E. Ryan, L. Nilsson, F. Shackley, L. Gothefors, K. Oymar, E. Miller, J. Storsaeter, and K. H. Mills. 1998. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in

children. Immunology 93:1-10.

122. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-

745.

123. Asokanathan, C., M. Corbel, and D. Xing. 2013. A CpG-containing oligodeoxynucleotide adjuvant for

acellular pertussis vaccine improves the protective response against Bordetella pertussis. Human vaccines & immunotherapeutics 9.

124. Cooper, C. L., H. L. Davis, M. L. Morris, S. M. Efler, M. A. Adhami, A. M. Krieg, D. W. Cameron, and J. Heathcote. 2004. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant

to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. Journal of clinical immunology

24:693-701.

125. Halperin, S. A., G. Van Nest, B. Smith, S. Abtahi, H. Whiley, and J. J. Eiden. 2003. A phase I study

of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21:2461-2467.

126. Brandtzaeg, P. 2010. Function of mucosa-associated lymphoid tissue in antibody formation. Immunological

investigations 39:303-355.

127. Mora, J. R., and U. H. von Andrian. 2009. Role of retinoic acid in the imprinting of gut-homing IgA-

secreting cells. Seminars in immunology 21:28-35.

128. Chadwick, S., C. Kriegel, and M. Amiji. 2010. Nanotechnology solutions for mucosal immunization.

Advanced drug delivery reviews 62:394-407.

129. Ishii, M., and N. Kojima. 2010. Mucosal adjuvant activity of oligomannose-coated liposomes for nasal

immunization. Glycoconjugate journal 27:115-123.

130. Schneider-Ohrum, K., and T. M. Ross. 2012. Virus-like particles for antigen delivery at mucosal surfaces.

Current topics in microbiology and immunology 354:53-73.

131. Lycke, N. 2012. Recent progress in mucosal vaccine development: potential and limitations. Nature

reviews. Immunology 12:592-605.

132. Cherry, J. D. 2010. The present and future control of pertussis. Clinical infectious diseases : an official

publication of the Infectious Diseases Society of America 51:663-667.

133. Klein, N. P., J. Bartlett, B. Fireman, A. Rowhani-Rahbar, and R. Baxter. 2013. Comparative effectiveness

of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics 131:e1716-1722.

134. Dias, W. O., A. A. van der Ark, M. A. Sakauchi, F. S. Kubrusly, A. F. Prestes, M. M. Borges, N. Furuyama, D. S. Horton, W. Quintilio, M. Antoniazi, B. Kuipers, B. A. van der Zeijst, and I. Raw.

2013. An improved whole cell pertussis vaccine with reduced content of endotoxin. Human vaccines & immunotherapeutics 9:339-348.

135. Asensio, C. J., M. E. Gaillard, G. Moreno, D. Bottero, E. Zurita, M. Rumbo, P. van der Ley, A. van der Ark, and D. Hozbor. 2011. Outer membrane vesicles obtained from Bordetella pertussis Tohama

expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. Vaccine 29:1649-1656.

136. Mielcarek, N., A. S. Debrie, D. Raze, J. Quatannens, J. Engle, W. E. Goldman, and C. Locht. 2006.

Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation. Vaccine 24 Suppl 2:S2-

54-55.

137. Fedele, G., M. Bianco, A. S. Debrie, C. Locht, and C. M. Ausiello. 2011. Attenuated Bordetella pertussis

vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response. Journal of immunology 186:5388-5396.

138. Skerry, C. M., and B. P. Mahon. 2011. A live, attenuated Bordetella pertussis vaccine provides long-term

protection against virulent challenge in a murine model. Clinical and vaccine immunology : CVI 18:187-

193.

139. Feunou, P. F., H. Kammoun, A. S. Debrie, N. Mielcarek, and C. Locht. 2010. Long-term immunity

against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine

28:7047-7053.

140. Gaillard, M. E., D. Bottero, A. Errea, M. Ormazabal, M. E. Zurita, G. Moreno, M. Rumbo, C. Castuma, E. Bartel, D. Flores, P. van der Ley, A. van der Ark, and F. H. D. 2014. Acellular pertussis vaccine based

6